Monday November 23 2009 | Biotechnology feed | All feeds

BioPortfolio Biotechnology Pharmaceutical Healthcare Medical Life Science Drug Discovery Disease

Leukemia Myeloid Chronic

Download PDF containing detailed information.PDF Version

Image Results

Loading...

Recent Publications on Leukemia Myeloid Chronic:

Pubmed Logo
Cytogenetic, fluorescence in situ hybridization, and molecular characterization of chronic myeloid leukemia in chronic phase with four BCR/ABL1 fusion signals: a case report.
We report a case of chronic myeloid leukemia in chronic stage with 48...
13th November, 2009
Division of Genetics, Department of Pathology, V. Macarena University Cancer Genet Cytogenet. 2009 Nov;195(1):71-4.
DOI Direct Link
A chronic myeloid leukemia patient with atypical karyotype and BCR-ABL e13a3 transcript caused by complex chromosome rearrangement.
Philadelphia (Ph) chromosome as a result of t (9; 22) (q34; q11) is...
13th November, 2009
Division of Bone Marrow Transplantation, Niigata University Medical and Int J Hematol. 2009 Sep;90(2):230-4. Epub 2009 Jun 30.
DOI Direct Link
Chronic myeloproliferative diseases with and without the Ph chromosome: some unresolved issues.
Ph-positive chronic myeloid leukemia (CML) and Ph-negative chronic...
6th November, 2009
Department of Haematology, Imperial College at Hammersmith Hospital, Leukemia. 2009 Oct;23(10):1708-15. Epub 2009 Jul 30.
DOI Direct Link
Nilotinib for imatinib-resistant or -intolerant chronic myeloid leukemia in chronic phase, accelerated phase, or blast crisis: a single- and multiple-dose, open-label pharmacokinetic study in Chinese patients.
BACKGROUND: Nilotinib, an oral second-generation Bcr-Abi tyrosine kinase...
29th October, 2009
Rui Jin Hospital, Shanghai Jiao Tong University School of Medicine, Clin Ther. 2009 Jul;31(7):1568-75.
DOI Direct Link
High-dose imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: high rates of rapid cytogenetic and molecular responses.
PURPOSE: Long-term clinical outcome data have established imatinib 400...
27th October, 2009
The University of Texas M. D. Anderson Cancer Center, Houston, TX 77030, J Clin Oncol. 2009 Oct 1;27(28):4754-9. Epub 2009 Aug 31.
DOI Direct Link

View more research publications.

Press Releases About Leukemia Myeloid Chronic:

BioPortfolio Logo
Reportlinker Adds Power Wheelchair Market Shares, Strategies, and Forecasts, Worldwide, 2009 to 2015 20th November, 2009 Reportlinker
NEW YORK, Nov. 20 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue. Power Wheelchair Market Shares, Strategies, and Forecasts, Worldwide,
Reportlinker Adds Global Self Monitoring Blood Glucose Market (SMBG): Increasing Adoption to Drive Growth 20th November, 2009 Reportlinker
NEW YORK, Nov. 20 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue. Global Self Monitoring Blood Glucose Market (SMBG): Increasing Adoption to
Aegera Therapeutics Initiates a Randomized Phase 2B Study with AEG35156 for the Treatment of Acute Myeloid Leukemia (AML) 19th November, 2009 AEGERA THERAPEUTICS INC.
MONTREAL, Nov. 19 /PRNewswire/ - Aegera Therapeutics Inc. announced today the dosing of the first patient in a randomized Phase 2B study of AEG35156, a targeted antisense therapeutic in mid-stage
Reportlinker Adds Pulmonary Drug Delivery Technologies - A Global Market Perspective 18th November, 2009 Reportlinker
NEW YORK, Nov. 18 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue. Pulmonary Drug Delivery Technologies - A Global Market Perspective http:/
/C O R R E C T I O N -- Education for Health/ 18th November, 2009
LONDON, November 18 /PRNewswire/ -- In the news release, "Mainstay of the Global Workforce - 40-65 Year Olds - Hit Hardest by Chronic Obstructive Pulmonary Disease (COPD)" issued on 18 Nov

BioNews Results for Leukemia Myeloid Chronic:

RSS Logo
BioPortfolio Logo
Data on Synta Pharmaceuticals' STA-9090 synthetic inhibitor of Hsp90 presented
News-Medical.Net:  Nov 18 2009 2:01PM Matching: leukemia myeloid chronic
Asuragen and Life Technologies Pool Resources to Develop CML Diagnostic
Genetic Engineering News:  Nov 18 2009 6:41PM Matching: leukemia myeloid chronic
Asuragen enters into an exclusive agreement with Life Technologies
News-Medical.Net:  Nov 18 2009 12:06PM Matching: leukemia myeloid chronic
Asuragen Signs Development and Worldwide Distribution Agreement with Life Technologies
Genetic Engineering News:  Nov 18 2009 9:23AM Matching: leukemia myeloid chronic
Allogeneic hematopoietic stem cell transplantation (alloSCT) for chronic myeloid leukemia in the imatinib era; Evaluation of its impact within a subgroup of the randomized German CML Study IV
MDLinx:  Nov 20 2009 11:41AM Matching: leukemia myeloid chronic
Promote your company here: BioNewsCast - Press Release Distribution

View more news.

BioPortfolio Ltd. offers e-mail and postal lists for Leukemia Myeloid Chronic scientists - we have details of around 67 individuals working on Leukemia Myeloid Chronic .


This page has been viewed 266 times
Recent Search Terms used to find this page: leukemia myeloid chronic | dose escalation and chronic myeloid | biochemistry leukemia of myleoid seris | biochemistry leukemia of myleoid seris | leukemia myeloid chr | .
Browse BioPortfolio's InDepth service - alphabetically: A B C D E F G H I J K L M N O P Q R S T U V W X Y Z or by Most Publications, recently searched for, or most viewed.

Search for Leukemia Myeloid Chronic across BioPortfolio, or for Leukemia Myeloid Chronic Research Reports
Wikipedia excerpt, where present, licenced under the GNU Free Documentation License. Resources from the NCBI applied. Selected MeSH subject headings created and maintained by the US NLM are used in conjunction with additional keywords. 2006-2008 MeSH. Thumbshots from Thumbshots.org

 

Nothing in this website should be used in place of personal medical advice from your own qualified medical practitioner.

All rights reserved. All other trademarks recognized.
Copyright 1997-2009 - BioPortfolio Limited.